Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia

Miao Hu, Ya Ling Yang, Paul Chan, Brian Tomlinson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: Cutaneous flushing with niacin varies between individuals and is substantially reduced by concomitant laropiprant. We investigated associations between baseline phenotypes and selected genotypes and flushing symptoms with niacin/laropiprant combination. Patients & methods: Flushing symptoms were quantified in 196 Chinese dyslipidaemic patients treated with niacin/laropiprant, and associations with phenotypes and selected polymorphisms were analyzed. Results: Moderate or severe flushing was associated with lower body mass index and the rs2279238 polymorphism in the LXRα on multivariate regression analysis and these factors accounted for 18.9% of the total variance. Conclusion: Lower body mass index and the LXRα polymorphism appear to be associated with flushing symptoms with niacin/laropiprant. Whether these findings can be applicable to other niacin formulations without laropiprant needs to be verified.

Original languageEnglish
Pages (from-to)1387-1397
Number of pages11
JournalPharmacogenomics
Volume16
Issue number12
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Niacin
Pharmacogenetics
Hong Kong
Dyslipidemias
Skin
Body Mass Index
Phenotype
Multivariate Analysis
Genotype
Regression Analysis
MK-0524

Keywords

  • flushing
  • laropiprant
  • LXRα
  • niacin

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia. / Hu, Miao; Yang, Ya Ling; Chan, Paul; Tomlinson, Brian.

In: Pharmacogenomics, Vol. 16, No. 12, 01.08.2015, p. 1387-1397.

Research output: Contribution to journalArticle

@article{ec316947b48e4489b1e45dd706984159,
title = "Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia",
abstract = "Aim: Cutaneous flushing with niacin varies between individuals and is substantially reduced by concomitant laropiprant. We investigated associations between baseline phenotypes and selected genotypes and flushing symptoms with niacin/laropiprant combination. Patients & methods: Flushing symptoms were quantified in 196 Chinese dyslipidaemic patients treated with niacin/laropiprant, and associations with phenotypes and selected polymorphisms were analyzed. Results: Moderate or severe flushing was associated with lower body mass index and the rs2279238 polymorphism in the LXRα on multivariate regression analysis and these factors accounted for 18.9{\%} of the total variance. Conclusion: Lower body mass index and the LXRα polymorphism appear to be associated with flushing symptoms with niacin/laropiprant. Whether these findings can be applicable to other niacin formulations without laropiprant needs to be verified.",
keywords = "flushing, laropiprant, LXRα, niacin",
author = "Miao Hu and Yang, {Ya Ling} and Paul Chan and Brian Tomlinson",
year = "2015",
month = "8",
day = "1",
doi = "10.2217/pgs.15.79",
language = "English",
volume = "16",
pages = "1387--1397",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia

AU - Hu, Miao

AU - Yang, Ya Ling

AU - Chan, Paul

AU - Tomlinson, Brian

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Aim: Cutaneous flushing with niacin varies between individuals and is substantially reduced by concomitant laropiprant. We investigated associations between baseline phenotypes and selected genotypes and flushing symptoms with niacin/laropiprant combination. Patients & methods: Flushing symptoms were quantified in 196 Chinese dyslipidaemic patients treated with niacin/laropiprant, and associations with phenotypes and selected polymorphisms were analyzed. Results: Moderate or severe flushing was associated with lower body mass index and the rs2279238 polymorphism in the LXRα on multivariate regression analysis and these factors accounted for 18.9% of the total variance. Conclusion: Lower body mass index and the LXRα polymorphism appear to be associated with flushing symptoms with niacin/laropiprant. Whether these findings can be applicable to other niacin formulations without laropiprant needs to be verified.

AB - Aim: Cutaneous flushing with niacin varies between individuals and is substantially reduced by concomitant laropiprant. We investigated associations between baseline phenotypes and selected genotypes and flushing symptoms with niacin/laropiprant combination. Patients & methods: Flushing symptoms were quantified in 196 Chinese dyslipidaemic patients treated with niacin/laropiprant, and associations with phenotypes and selected polymorphisms were analyzed. Results: Moderate or severe flushing was associated with lower body mass index and the rs2279238 polymorphism in the LXRα on multivariate regression analysis and these factors accounted for 18.9% of the total variance. Conclusion: Lower body mass index and the LXRα polymorphism appear to be associated with flushing symptoms with niacin/laropiprant. Whether these findings can be applicable to other niacin formulations without laropiprant needs to be verified.

KW - flushing

KW - laropiprant

KW - LXRα

KW - niacin

UR - http://www.scopus.com/inward/record.url?scp=84941626815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941626815&partnerID=8YFLogxK

U2 - 10.2217/pgs.15.79

DO - 10.2217/pgs.15.79

M3 - Article

C2 - 26226939

AN - SCOPUS:84941626815

VL - 16

SP - 1387

EP - 1397

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 12

ER -